Invention Grant
US08946159B2 Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
有权
给予α5和bgr的拮抗剂1用于抗血管生成和癌症治疗
- Patent Title: Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
- Patent Title (中): 给予α5和bgr的拮抗剂1用于抗血管生成和癌症治疗
-
Application No.: US13374369Application Date: 2011-12-22
-
Publication No.: US08946159B2Publication Date: 2015-02-03
- Inventor: Xiaodong Feng
- Applicant: Xiaodong Feng
- Applicant Address: US CA Elk Grove
- Assignee: California Northstate College of Pharmacy, LLC
- Current Assignee: California Northstate College of Pharmacy, LLC
- Current Assignee Address: US CA Elk Grove
- Agency: Syndicated Law, PC
- Agent Brian S. Boyer
- Main IPC: A61K38/00
- IPC: A61K38/00 ; A61P35/00 ; C07K14/515 ; A61K38/17 ; A61K38/18 ; A61K45/06
Abstract:
A combination therapy is provided and is directed to pharmaceutical compositions and methods for administering a combination of an α5β1 antagonist with an α2β1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. The compositions and methods include a combined administration of VLO4 and VP12 (ECL12).
Public/Granted literature
- US20130165380A1 Administration of an antagonist of a5ß1 for anti-angiogenesis and cancer treatment Public/Granted day:2013-06-27
Information query
IPC分类:
